Table 2.

Incident detection of HPV among HIV-positive MSM in San Francisco (N = 369).

HPV type	Na	Number incident infections	2-year cumulative proportionb	Total PY	Incidence rate (incident infection/100 PY)c	(95% CI)d
6	221	5	2.3	348	1.4	(0.5–3.4)
11	268	4	1.5	410	1	(0.3–2.5)
16	222	12	5.4	342	3.5	(1.8–6.1)
18	268	15	5.6	407	3.7	(2.1–6.1)
26	360	1	0.3	555	0.2	(0–1)
31	275	9	3.3	417	2.2	(1–4.1)
32	349	4	1.1	538	0.7	(0.2–1.9)
33	278	11	4	423	2.6	(1.3–4.7)
35	354	0	0	551	0	(0–0.7)
39	333	4	1.2	511	0.8	(0.2–2)
40	351	5	1.4	540	0.9	(0.3–2.2)
45	283	8	2.8	433	1.8	(0.8–3.6)
51	305	2	0.7	470	0.4	(0.1–1.5)
52	291	5	1.7	450	1.1	(0.4–2.6)
53	278	8	2.9	428	1.9	(0.8–3.7)
54	333	4	1.2	513	0.8	(0.2–2)
55	357	1	0.3	550	0.2	(0–1)
56	335	8	2.4	518	1.6	(0.7–3.1)
58	283	10	3.5	434	2.3	(1.1–4.2)
59	302	7	2.3	465	1.5	(0.6–3.1)
61	308	13	4.2	474	2.7	(1.5–4.7)
68	312	1	0.3	486	0.2	(0–1.1)
69	358	0	0	555	0	(.-0.7)
70	280	8	2.9	429	1.9	(0.8–3.7)
73	326	3	0.9	506	0.6	(0.1–1.7)
82	359	1	0.3	558	0.2	(0–1)
83	321	2	0.6	496	0.4	(0–1.5)
84	317	8	2.5	489	1.6	(0.7–3.2)
Any type	369	122	33.1	573	21.3	(17.7–25.4)
Oncogenic typese	369	76	20.6	573	13.3	(10.5–16.6)
Nononcogenic types	369	37	10	573	6.5	(4.5–8.9)

CI, confidence interval; HPV, human papillomavirus; PY, person-years. Incident detection infection, negative for type-specific HPV DNA at baseline followed by two consecutive detections of a specific type of HPV.

^aParticipants at risk for HPV type (negative for type at baseline). Participants beta-globin-negative at baseline excluded from analysis.

^bNumber of incident infections/participants negative for type-specific HPV DNA at baseline.

^cNumber of incident infections/person-years at risk.

^d95% exact Poisson confidence intervals.

^eHPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82.